- Home
- CRF vs TSHA Comparison
CRF vs TSHA Comparison
Compare CRF & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRF | TSHA |
|---|---|---|
| Founded | 1973 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRF | TSHA |
|---|---|---|
| Price | $7.97 | $4.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.22 |
| AVG Volume (30 Days) | 1.1M | ★ 3.8M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 18.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | ★ $11,461,786.00 | $6,310,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $5.38 | ★ N/A |
| Revenue Growth | ★ 6.53 | N/A |
| 52 Week Low | $5.70 | $1.05 |
| 52 Week High | $9.56 | $5.51 |
Technical Indicators
Market Signals| Indicator | CRF | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 59.35 |
| Support Level | $7.58 | $3.92 |
| Resistance Level | $7.92 | $4.34 |
| Average True Range (ATR) | 0.11 | 0.29 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 76.47 | 86.27 |
Price Performance
Historical ComparisonAbout CRF Cornerstone Total Return Fund Inc. (The)
Cornerstone Total Return Fund Inc is a diversified closed-end management company. Its objective is to seek capital appreciation with current income as a secondary objective. The company invests in sectors such as Information Technology; Health Care; Financials; Communication Services; Consumer Discretionary; Industrials; Exchange-Traded Funds; Utilities; Energy; Real Estate and others.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.